PsychedelicNewsBreaks

MondayJun 29, 2020 1:27 pm

PsychedelicNewsBreaks – Mushrooms Take the Stage in First-Ever PsyTech Summit

The new era of mushrooms was featured in a recent Forbes article by Sara Brittany Somerset titled, “Psychedelic Events Are Going Mainstream, Where The Much-Maligned Mushroom Industry Focuses On Mental Health.” The article, which discusses psychedelics taking the stage in consumption and investing, reads, “PsychedeliTech, a ground-breaking new conference, incubator and discovery platform for psychedelic medicine will host Rick Doblin, Ph.D., founder and executive director of the Multidisciplinary Association for Psychedelic Studies (“MAPS”) as the keynote speaker at the first-ever PsyTech Summit, a forum for psychedelic science, innovation and investment conference, in Israel.” To view the full article, visit http://ibn.fm/tivNo…

Continue Reading

MondayJun 22, 2020 11:46 am

PsychedelicNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) Announces Regulatory Review

Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496), a human optimization sciences company with an emphasis on ketamine and psychedelic medicine, today announced that it has been selected for a continuous disclosure review by the British Columbia Securities Commission (the “Commission”).  The review relates to Champignon’s disclosure obligations since it became a reporting issuer on February 6, 2020 and includes a review of the disclosure surrounding certain recent acquisitions completed by the Company. “With the recent growth and interest in our industry, ensuring our disclosure obligations are satisfied is at the forefront of our attention.  Ensuring fulsome and timely disclosure…

Continue Reading

FridayJun 19, 2020 2:12 pm

PsychedelicNewsBreaks – Why Pure Extracts Corp. Is ‘One to Watch’

Headquartered in Pemberton, British Columbia, Pure Extracts is a private, plant-based extraction company with a new vertical in functional mushrooms. A recent article discussing the company reads, “Current research is finding psychedelic benefits including anti-tumor, anti-viral, detoxification, immune function and mental wellness. As such, psychedelic compounds are now being examined by leading medical research and academic institutions for treatment of depression, PTSD, anxiety, bipolar disorder, obesity, narcolepsy, OCD, Alzheimer’s, ADHD, and drug and alcohol dependence. In 2020, the FDA granted breakthrough therapy status to psychedelics for treatment-resistant depression, with approvals anticipated in 2021. . . . Pure Extracts is well…

Continue Reading

FridayJun 19, 2020 10:19 am

PsychedelicNewsBreaks – Champignon Brands Inc.’s (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) Dr. McIntyre / CRTCE Published in Two Peer Reviewed Study Journals

Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496), a human optimization sciences company with an emphasis on ketamine and psychedelic medicine, continues to highlight the scientific merit of its ketamine treatments for Major Depressive Disorder (“MDD”) while demonstrating rapid onset efficacy and safety of its treatment processes. To this accord, the Company today announced that its Chief Executive Officer, Dr. Roger McIntyre, and the Canadian Rapid Treatment Centre of Excellence (the “CRTCE”) have been recently published in two peer reviewed study journals (the “Peer Reviewed Studies”) focusing on ketamine’s safety, tolerability and effectiveness. “The publications of data as it relates…

Continue Reading

WednesdayJun 17, 2020 1:25 pm

PsychedelicNewsBreaks – Mind Medicine Inc. (NEO: MMED) (OTCQB: MMEDF) Announces Phase 2 Clinical Trial of LSD to Treat Cluster Headaches Begins Treating Patients

Mind Medicine (NEO: MMED) (OTCQB: MMEDF) (“MindMed”), a leading neuro-pharmaceutical company focused on psychedelic inspired medicines, recently announced that the Phase 2 clinical trial evaluating LSD for the treatment of cluster headaches at University Hospital Basel's Liechti Lab has started treating patients. MindMed previously established an ongoing R&D collaboration with the University Hospital Basel's Liechti Lab to evaluate various therapeutic uses of psychedelics and next-gen psychedelic therapies. The double-blind, randomized, placebo-controlled two-phase cross-over study is examining the effects of an oral LSD pulse regimen in 30 patients with cluster headaches. “As we continue on our mission to discover, develop and…

Continue Reading

MondayJun 15, 2020 9:41 am

PsychedelicNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) Provides Corporate Update

Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496), a human optimization sciences company with an emphasis on ketamine and psychedelic medicine, on Friday provided a corporate update. Since commencing trading on March 2, 2020, the Company has expanded its initiatives and rapidly executed on such initiatives to position it as a leading publicly traded psychedelic medicine company developing novel rapid onset treatments for depression, post-traumatic stress disorder (“PTSD”), and substance-use disorders (“SUD”) via the clinical delivery of ketamine and ketamine-derivatives. In the update, the Company shared its corporate advancements and achievements over the last quarter, which target key segments in…

Continue Reading

MondayJun 08, 2020 11:11 am

PsychedelicNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) Engages Toronto-based Dalriada to Advance NCE IP Portfolio

Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496), a human optimization sciences company with an emphasis on ketamine and psychedelic medicine, today announced its selection of Toronto-based Dalriada Drug Discovery Inc. (“Dalriada”) to advance its new chemical entity (“NCE”) IP portfolio as it pertains to ketamine and psilocybin/psilicin molecular scaffolds. According to the update, Dalriada, a leading contract research organization (“CRO”) in the drug discovery space, will lead Champignon’s new drug discovery programs in the NCE arena and further provide integrated R&D support to accelerate the Company’s existing preclinical assets and ongoing development of proprietary delivery platforms. “It is with…

Continue Reading

ThursdayJun 04, 2020 2:14 pm

PsychedelicNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) Names New CEO

Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496), a human-optimization sciences company with an emphasis on ketamine and psychedelic medicine, recently named Dr. Roger McIntyre as chief executive officer. An article discussing the company reads, “In his new role, Dr. Roger McIntyre brings impressive experience in the ketamine and psychedelic medicine space, a key focus area for Champignon. . . . ‘My overarching aim as chief executive officer is to establish Champignon as the apotheosis of integrated ketamine treatment delivery and the commercialization of our own IP psychedelic-based treatments,’ McIntyre stated in a news release. ‘The clinical infrastructure, complementary asset…

Continue Reading

FridayMay 29, 2020 10:09 am

PsychedelicNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) Announces Voluntary Share Lock-Up, Engagement of Gold Standard Media for Marketing and Consulting Services

Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496), a human optimization sciences company with an emphasis on ketamine and psychedelic medicine, today announced that certain shareholders have agreed to a voluntary resale restriction period covering 17,840,000 common shares extending the period of time before the shares become free trading to July 15, 2020. According to the update, these shares were previously only subject to a statutory hold period. In addition, Champignon Brands also announced its engagement of Gold Standard Media, LLC (“GSM”) to provide marketing and consulting services to raise public awareness of the company, with a specific emphasis on…

Continue Reading

TuesdayMay 26, 2020 9:17 am

PsychedelicNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) Appoints New Member to Board of Directors

Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496), a human optimization sciences company with an emphasis on ketamine and psychedelic medicine, on Monday announced the appointment of Dr. Bill Wilkerson, LL.D. (Hon), an 8-time award-winning pioneer in workplace mental health, to its board of directors. In addition, the company reported the resignation of Mr. Joe Perino from its board of directors. “We are thrilled to welcome Dr. Wilkerson to our board of directors. I look forward to working with him on a personal level as his decades of thought leadership in mental health and extensive global network will be vital…

Continue Reading